321 related articles for article (PubMed ID: 16951243)
1. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
LaCasse EC; Cherton-Horvat GG; Hewitt KE; Jerome LJ; Morris SJ; Kandimalla ER; Yu D; Wang H; Wang W; Zhang R; Agrawal S; Gillard JW; Durkin JP
Clin Cancer Res; 2006 Sep; 12(17):5231-41. PubMed ID: 16951243
[TBL] [Abstract][Full Text] [Related]
2. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
3. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
4. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro.
Connolly K; Mitter R; Muir M; Jodrell D; Guichard S
Cancer Chemother Pharmacol; 2009 Jul; 64(2):307-16. PubMed ID: 19034449
[TBL] [Abstract][Full Text] [Related]
5. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156.
LaCasse EC
Cancer Lett; 2013 May; 332(2):215-24. PubMed ID: 22776562
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
[TBL] [Abstract][Full Text] [Related]
7. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640.
Lacasse EC; Kandimalla ER; Winocour P; Sullivan T; Agrawal S; Gillard JW; Durkin J
Ann N Y Acad Sci; 2005 Nov; 1058():215-34. PubMed ID: 16394139
[TBL] [Abstract][Full Text] [Related]
8. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics.
McManus DC; Lefebvre CA; Cherton-Horvat G; St-Jean M; Kandimalla ER; Agrawal S; Morris SJ; Durkin JP; Lacasse EC
Oncogene; 2004 Oct; 23(49):8105-17. PubMed ID: 15378029
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents.
Holt SV; Brookes KE; Dive C; Makin GW
Oncol Rep; 2011 Apr; 25(4):1177-81. PubMed ID: 21286665
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
[TBL] [Abstract][Full Text] [Related]
11. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
[TBL] [Abstract][Full Text] [Related]
12. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Schimmer AD; Estey EH; Borthakur G; Carter BZ; Schiller GJ; Tallman MS; Altman JK; Karp JE; Kassis J; Hedley DW; Brandwein J; Xu W; Mak DH; LaCasse E; Jacob C; Morris SJ; Jolivet J; Andreeff M
J Clin Oncol; 2009 Oct; 27(28):4741-6. PubMed ID: 19652057
[TBL] [Abstract][Full Text] [Related]
14. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
15. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
Carter BZ; Mak DH; Morris SJ; Borthakur G; Estey E; Byrd AL; Konopleva M; Kantarjian H; Andreeff M
Apoptosis; 2011 Jan; 16(1):67-74. PubMed ID: 20938744
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
17. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings J; Ward TH; LaCasse E; Lefebvre C; St-Jean M; Durkin J; Ranson M; Dive C
Br J Cancer; 2005 Feb; 92(3):532-8. PubMed ID: 15685240
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC.
Pan Q; Liu B; Liu J; Cai R; Liu X; Qian C
Acta Oncol; 2008; 47(1):135-44. PubMed ID: 17934893
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression.
Tu SP; Sun YW; Cui JT; Zou B; Lin MC; Gu Q; Jiang SH; Kung HF; Korneluk RG; Wong BC
Cancer; 2010 Mar; 116(5):1252-63. PubMed ID: 20082449
[TBL] [Abstract][Full Text] [Related]
20. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
